Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Source: SeekingAlpha
2026-02-09 11:15:40 ET
Thesis overview
Century Therapeutics ( IPSC ) is developing induced pluripotent stem cell ((iPSC))-derived therapies for the treatment of type I diabetes mellitus ((T1DM)), autoimmune diseases and oncology indications. Their iPSC platform allows scalable and homogeneous production of cell therapies and is combined with "Allo-Evasion" technology which allows cell therapies to evade the recipient's immune system (a major hurdle in allogeneic approaches)....
Read the full article on Seeking Alpha
For further details see:
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics Inc.
NASDAQ: IPSC
IPSC Trading
-0.39% G/L:
$2.55 Last:
414,672 Volume:
$2.51 Open:
IPSC Latest News
February 25, 2026 08:00:00 am
Century Therapeutics to Participate in Upcoming Investor Conferences in March
IPSC Stock Data
$358,397,419
106,369,480
5.86%
10
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
